SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

UPDATE: Goldman Initiates Halozyme Therapeutics With Buy, $24 Target Notes 'Moving away from its own drugs, a newer, simpler and low(er) risk biotech story emerges'

Benzinga · 01/08/2020 18:34